CN114410726A - 三环二萜类化合物的c-14和c-12位羟化酶 - Google Patents
三环二萜类化合物的c-14和c-12位羟化酶 Download PDFInfo
- Publication number
- CN114410726A CN114410726A CN202210059174.XA CN202210059174A CN114410726A CN 114410726 A CN114410726 A CN 114410726A CN 202210059174 A CN202210059174 A CN 202210059174A CN 114410726 A CN114410726 A CN 114410726A
- Authority
- CN
- China
- Prior art keywords
- enzyme
- leu
- abietane
- hydroxylation
- tricyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 diterpene compounds Chemical class 0.000 title claims abstract description 40
- 229930004069 diterpene Natural products 0.000 title claims description 14
- 108010074633 Mixed Function Oxygenases Proteins 0.000 title description 4
- 102000008109 Mixed Function Oxygenases Human genes 0.000 title description 4
- 102000004190 Enzymes Human genes 0.000 claims abstract description 38
- 108090000790 Enzymes Proteins 0.000 claims abstract description 38
- 238000005805 hydroxylation reaction Methods 0.000 claims abstract description 25
- 241000830536 Tripterygium wilfordii Species 0.000 claims abstract description 24
- 230000033444 hydroxylation Effects 0.000 claims abstract description 24
- 235000015398 thunder god vine Nutrition 0.000 claims abstract description 24
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 20
- 229940118781 dehydroabietic acid Drugs 0.000 claims abstract description 18
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 15
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 15
- 239000002157 polynucleotide Substances 0.000 claims abstract description 15
- NFWKVWVWBFBAOV-MISYRCLQSA-N dehydroabietic acid Chemical compound OC(=O)[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 NFWKVWVWBFBAOV-MISYRCLQSA-N 0.000 claims abstract description 14
- QUUCYKKMFLJLFS-UHFFFAOYSA-N Dehydroabietan Natural products CC1(C)CCCC2(C)C3=CC=C(C(C)C)C=C3CCC21 QUUCYKKMFLJLFS-UHFFFAOYSA-N 0.000 claims abstract description 13
- NFWKVWVWBFBAOV-UHFFFAOYSA-N Dehydroabietic acid Natural products OC(=O)C1(C)CCCC2(C)C3=CC=C(C(C)C)C=C3CCC21 NFWKVWVWBFBAOV-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000005899 aromatization reaction Methods 0.000 claims abstract description 10
- 230000006870 function Effects 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 51
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 37
- 239000013604 expression vector Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 26
- 241000196324 Embryophyta Species 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 8
- 230000003197 catalytic effect Effects 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 229930000074 abietane Natural products 0.000 claims description 4
- 150000004141 diterpene derivatives Chemical class 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- STIVVCHBLMGYSL-ZYNAIFEFSA-N abietane Chemical compound CC1(C)CCC[C@]2(C)[C@H]3CC[C@H](C(C)C)C[C@@H]3CC[C@H]21 STIVVCHBLMGYSL-ZYNAIFEFSA-N 0.000 claims description 3
- 150000001993 dienes Chemical class 0.000 claims description 3
- 125000000567 diterpene group Chemical group 0.000 claims description 3
- 229930183118 Tanshinone Natural products 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000009395 breeding Methods 0.000 claims description 2
- 230000001488 breeding effect Effects 0.000 claims description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 1
- 238000005906 dihydroxylation reaction Methods 0.000 claims 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 abstract description 25
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 abstract description 25
- 108010045510 NADPH-Ferrihemoprotein Reductase Proteins 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000006555 catalytic reaction Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000543 intermediate Substances 0.000 abstract 2
- SWOVVKGLGOOUKI-ZHGGVEMFSA-N triptonide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)C(=O)[C@]21[C@H]3O1 SWOVVKGLGOOUKI-ZHGGVEMFSA-N 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 41
- 239000000047 product Substances 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 34
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 30
- 239000007788 liquid Substances 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 230000001580 bacterial effect Effects 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 21
- 239000013598 vector Substances 0.000 description 21
- 239000012634 fragment Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000010367 cloning Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 238000000855 fermentation Methods 0.000 description 13
- 230000004151 fermentation Effects 0.000 description 13
- 230000009466 transformation Effects 0.000 description 13
- 238000002156 mixing Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000010276 construction Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000000246 agarose gel electrophoresis Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 241001052560 Thallis Species 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000012795 verification Methods 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 108010001498 Galectin 1 Proteins 0.000 description 4
- 102100021736 Galectin-1 Human genes 0.000 description 4
- 102100024637 Galectin-10 Human genes 0.000 description 4
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 4
- 101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 4
- 101150053185 P450 gene Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- AYDJDNNMKHXZOQ-MISYRCLQSA-N (1r,4as,10ar)-6-hydroxy-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylic acid Chemical compound OC(=O)[C@@](C)([C@@H]1CC2)CCC[C@]1(C)C1=C2C=C(C(C)C)C(O)=C1 AYDJDNNMKHXZOQ-MISYRCLQSA-N 0.000 description 3
- AYDJDNNMKHXZOQ-UHFFFAOYSA-N 12-hydroxydehydroabietic acid Natural products C1CC2C(C)(C(O)=O)CCCC2(C)C2=C1C=C(C(C)C)C(O)=C2 AYDJDNNMKHXZOQ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101001112118 Homo sapiens NADPH-cytochrome P450 reductase Proteins 0.000 description 3
- 241000235058 Komagataella pastoris Species 0.000 description 3
- 102100023897 NADPH-cytochrome P450 reductase Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241001452677 Ogataea methanolica Species 0.000 description 3
- IXELFRRANAOWSF-CYBMUJFWSA-N ajoene Natural products C=CCSSC=CC[S@](=O)CC=C IXELFRRANAOWSF-CYBMUJFWSA-N 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 238000002983 circular dichroism Methods 0.000 description 3
- IXELFRRANAOWSF-UHFFFAOYSA-N cis-ajoene Natural products C=CCSSC=CCS(=O)CC=C IXELFRRANAOWSF-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- OKTJSMMVPCPJKN-IGMARMGPSA-N Carbon-12 Chemical compound [12C] OKTJSMMVPCPJKN-IGMARMGPSA-N 0.000 description 2
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 101100545229 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ZDS2 gene Proteins 0.000 description 2
- 101100113084 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mcs2 gene Proteins 0.000 description 2
- 101100167209 Ustilago maydis (strain 521 / FGSC 9021) CHS8 gene Proteins 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229940094933 n-dodecane Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 150000005671 trienes Chemical class 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- COEXAQSTZUWMRI-STQMWFEESA-N (2s)-1-[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 COEXAQSTZUWMRI-STQMWFEESA-N 0.000 description 1
- KPXIBWGPZSPABK-FXAWDEMLSA-N (3bR,9bS)-6-hydroxy-9b-methyl-7-propan-2-yl-3,3b,4,5,10,11-hexahydronaphtho[2,1-e]isobenzofuran-1-one Chemical compound C1C[C@]2(C)C3=CC=C(C(C)C)C(O)=C3CC[C@H]2C2=C1C(=O)OC2 KPXIBWGPZSPABK-FXAWDEMLSA-N 0.000 description 1
- IXELFRRANAOWSF-FNORWQNLSA-N (E)-Ajoene Chemical compound C=CCSS\C=C\CS(=O)CC=C IXELFRRANAOWSF-FNORWQNLSA-N 0.000 description 1
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- WDIYWDJLXOCGRW-ACZMJKKPSA-N Ala-Asp-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WDIYWDJLXOCGRW-ACZMJKKPSA-N 0.000 description 1
- WGDNWOMKBUXFHR-BQBZGAKWSA-N Ala-Gly-Arg Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N WGDNWOMKBUXFHR-BQBZGAKWSA-N 0.000 description 1
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 1
- MFMDKJIPHSWSBM-GUBZILKMSA-N Ala-Lys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFMDKJIPHSWSBM-GUBZILKMSA-N 0.000 description 1
- GKAZXNDATBWNBI-DCAQKATOSA-N Ala-Met-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N GKAZXNDATBWNBI-DCAQKATOSA-N 0.000 description 1
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010010777 Arg-Gly-Asp-Gly Proteins 0.000 description 1
- NGTYEHIRESTSRX-UWVGGRQHSA-N Arg-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NGTYEHIRESTSRX-UWVGGRQHSA-N 0.000 description 1
- PSOPJDUQUVFSLS-GUBZILKMSA-N Arg-Met-Cys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N PSOPJDUQUVFSLS-GUBZILKMSA-N 0.000 description 1
- YHZQOSXDTFRZKU-WDSOQIARSA-N Arg-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N)=CNC2=C1 YHZQOSXDTFRZKU-WDSOQIARSA-N 0.000 description 1
- GMUOCGCDOYYWPD-FXQIFTODSA-N Asn-Pro-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O GMUOCGCDOYYWPD-FXQIFTODSA-N 0.000 description 1
- GZXOUBTUAUAVHD-ACZMJKKPSA-N Asn-Ser-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GZXOUBTUAUAVHD-ACZMJKKPSA-N 0.000 description 1
- HCZQKHSRYHCPSD-IUKAMOBKSA-N Asn-Thr-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HCZQKHSRYHCPSD-IUKAMOBKSA-N 0.000 description 1
- SYZWMVSXBZCOBZ-QXEWZRGKSA-N Asn-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)N)N SYZWMVSXBZCOBZ-QXEWZRGKSA-N 0.000 description 1
- SDHFVYLZFBDSQT-DCAQKATOSA-N Asp-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N SDHFVYLZFBDSQT-DCAQKATOSA-N 0.000 description 1
- GWTLRDMPMJCNMH-WHFBIAKZSA-N Asp-Asn-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GWTLRDMPMJCNMH-WHFBIAKZSA-N 0.000 description 1
- RYEWQKQXRJCHIO-SRVKXCTJSA-N Asp-Asn-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 RYEWQKQXRJCHIO-SRVKXCTJSA-N 0.000 description 1
- FRSGNOZCTWDVFZ-ACZMJKKPSA-N Asp-Asp-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O FRSGNOZCTWDVFZ-ACZMJKKPSA-N 0.000 description 1
- PSLSTUMPZILTAH-BYULHYEWSA-N Asp-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PSLSTUMPZILTAH-BYULHYEWSA-N 0.000 description 1
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 1
- MYOHQBFRJQFIDZ-KKUMJFAQSA-N Asp-Leu-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYOHQBFRJQFIDZ-KKUMJFAQSA-N 0.000 description 1
- MYLZFUMPZCPJCJ-NHCYSSNCSA-N Asp-Lys-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MYLZFUMPZCPJCJ-NHCYSSNCSA-N 0.000 description 1
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 description 1
- 241000222128 Candida maltosa Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- SRIRHERUAMYIOQ-CIUDSAMLSA-N Cys-Leu-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SRIRHERUAMYIOQ-CIUDSAMLSA-N 0.000 description 1
- XZKJEOMFLDVXJG-KATARQTJSA-N Cys-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)N)O XZKJEOMFLDVXJG-KATARQTJSA-N 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- YNNXQZDEOCYJJL-CIUDSAMLSA-N Gln-Arg-Asp Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)CN=C(N)N YNNXQZDEOCYJJL-CIUDSAMLSA-N 0.000 description 1
- PRBLYKYHAJEABA-SRVKXCTJSA-N Gln-Arg-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O PRBLYKYHAJEABA-SRVKXCTJSA-N 0.000 description 1
- QENSHQJGWGRPQS-QEJZJMRPSA-N Gln-Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)N)C(O)=O)=CNC2=C1 QENSHQJGWGRPQS-QEJZJMRPSA-N 0.000 description 1
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 1
- LTUVYLVIZHJCOQ-KKUMJFAQSA-N Glu-Arg-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LTUVYLVIZHJCOQ-KKUMJFAQSA-N 0.000 description 1
- XKPOCESCRTVRPL-KBIXCLLPSA-N Glu-Cys-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XKPOCESCRTVRPL-KBIXCLLPSA-N 0.000 description 1
- JYXKPJVDCAWMDG-ZPFDUUQYSA-N Glu-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)N JYXKPJVDCAWMDG-ZPFDUUQYSA-N 0.000 description 1
- GMVCSRBOSIUTFC-FXQIFTODSA-N Glu-Ser-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMVCSRBOSIUTFC-FXQIFTODSA-N 0.000 description 1
- RQZGFWKQLPJOEQ-YUMQZZPRSA-N Gly-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CN)CN=C(N)N RQZGFWKQLPJOEQ-YUMQZZPRSA-N 0.000 description 1
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 1
- KQDMENMTYNBWMR-WHFBIAKZSA-N Gly-Asp-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O KQDMENMTYNBWMR-WHFBIAKZSA-N 0.000 description 1
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 1
- GAFKBWKVXNERFA-QWRGUYRKSA-N Gly-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 GAFKBWKVXNERFA-QWRGUYRKSA-N 0.000 description 1
- HFPVRZWORNJRRC-UWVGGRQHSA-N Gly-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN HFPVRZWORNJRRC-UWVGGRQHSA-N 0.000 description 1
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
- FULZDMOZUZKGQU-ONGXEEELSA-N Gly-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN FULZDMOZUZKGQU-ONGXEEELSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- KNNSUUOHFVVJOP-GUBZILKMSA-N His-Glu-Ser Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N KNNSUUOHFVVJOP-GUBZILKMSA-N 0.000 description 1
- MLZVJIREOKTDAR-SIGLWIIPSA-N His-Ile-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MLZVJIREOKTDAR-SIGLWIIPSA-N 0.000 description 1
- GJMHMDKCJPQJOI-IHRRRGAJSA-N His-Lys-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CN=CN1 GJMHMDKCJPQJOI-IHRRRGAJSA-N 0.000 description 1
- QEYUCKCWTMIERU-SRVKXCTJSA-N His-Lys-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N QEYUCKCWTMIERU-SRVKXCTJSA-N 0.000 description 1
- CGAMSLMBYJHMDY-ONGXEEELSA-N His-Val-Gly Chemical compound CC(C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N CGAMSLMBYJHMDY-ONGXEEELSA-N 0.000 description 1
- HGNUKGZQASSBKQ-PCBIJLKTSA-N Ile-Asp-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HGNUKGZQASSBKQ-PCBIJLKTSA-N 0.000 description 1
- LJKDGRWXYUTRSH-YVNDNENWSA-N Ile-Gln-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N LJKDGRWXYUTRSH-YVNDNENWSA-N 0.000 description 1
- PFPUFNLHBXKPHY-HTFCKZLJSA-N Ile-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)O)N PFPUFNLHBXKPHY-HTFCKZLJSA-N 0.000 description 1
- KLBVGHCGHUNHEA-BJDJZHNGSA-N Ile-Leu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O)N KLBVGHCGHUNHEA-BJDJZHNGSA-N 0.000 description 1
- YSGBJIQXTIVBHZ-AJNGGQMLSA-N Ile-Lys-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O YSGBJIQXTIVBHZ-AJNGGQMLSA-N 0.000 description 1
- JZNVOBUNTWNZPW-GHCJXIJMSA-N Ile-Ser-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N JZNVOBUNTWNZPW-GHCJXIJMSA-N 0.000 description 1
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
- SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235650 Kluyveromyces marxianus Species 0.000 description 1
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 description 1
- DBVWMYGBVFCRBE-CIUDSAMLSA-N Leu-Asn-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DBVWMYGBVFCRBE-CIUDSAMLSA-N 0.000 description 1
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 1
- VBZOAGIPCULURB-QWRGUYRKSA-N Leu-Gly-His Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N VBZOAGIPCULURB-QWRGUYRKSA-N 0.000 description 1
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 1
- CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 description 1
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- JLWZLIQRYCTYBD-IHRRRGAJSA-N Leu-Lys-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JLWZLIQRYCTYBD-IHRRRGAJSA-N 0.000 description 1
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 1
- FIICHHJDINDXKG-IHPCNDPISA-N Leu-Lys-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O FIICHHJDINDXKG-IHPCNDPISA-N 0.000 description 1
- BIZNDKMFQHDOIE-KKUMJFAQSA-N Leu-Phe-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 BIZNDKMFQHDOIE-KKUMJFAQSA-N 0.000 description 1
- XXXXOVFBXRERQL-ULQDDVLXSA-N Leu-Pro-Phe Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XXXXOVFBXRERQL-ULQDDVLXSA-N 0.000 description 1
- PWPBLZXWFXJFHE-RHYQMDGZSA-N Leu-Pro-Thr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O PWPBLZXWFXJFHE-RHYQMDGZSA-N 0.000 description 1
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 1
- ZDJQVSIPFLMNOX-RHYQMDGZSA-N Leu-Thr-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZDJQVSIPFLMNOX-RHYQMDGZSA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- ZGGVHTQAPHVMKM-IHPCNDPISA-N Leu-Trp-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCCN)C(=O)O)N ZGGVHTQAPHVMKM-IHPCNDPISA-N 0.000 description 1
- UFPLDOKWDNTTRP-ULQDDVLXSA-N Leu-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CC=C(O)C=C1 UFPLDOKWDNTTRP-ULQDDVLXSA-N 0.000 description 1
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 1
- CGHXMODRYJISSK-NHCYSSNCSA-N Leu-Val-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O CGHXMODRYJISSK-NHCYSSNCSA-N 0.000 description 1
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 1
- YNNPKXBBRZVIRX-IHRRRGAJSA-N Lys-Arg-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O YNNPKXBBRZVIRX-IHRRRGAJSA-N 0.000 description 1
- NDORZBUHCOJQDO-GVXVVHGQSA-N Lys-Gln-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O NDORZBUHCOJQDO-GVXVVHGQSA-N 0.000 description 1
- DRCILAJNUJKAHC-SRVKXCTJSA-N Lys-Glu-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DRCILAJNUJKAHC-SRVKXCTJSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- WOEDRPCHKPSFDT-MXAVVETBSA-N Lys-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCCCN)N WOEDRPCHKPSFDT-MXAVVETBSA-N 0.000 description 1
- PRSBSVAVOQOAMI-BJDJZHNGSA-N Lys-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN PRSBSVAVOQOAMI-BJDJZHNGSA-N 0.000 description 1
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 1
- YDDDRTIPNTWGIG-SRVKXCTJSA-N Lys-Lys-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O YDDDRTIPNTWGIG-SRVKXCTJSA-N 0.000 description 1
- DYJOORGDQIGZAS-DCAQKATOSA-N Lys-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N DYJOORGDQIGZAS-DCAQKATOSA-N 0.000 description 1
- RMOKGALPSPOYKE-KATARQTJSA-N Lys-Thr-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMOKGALPSPOYKE-KATARQTJSA-N 0.000 description 1
- RQILLQOQXLZTCK-KBPBESRZSA-N Lys-Tyr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O RQILLQOQXLZTCK-KBPBESRZSA-N 0.000 description 1
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 1
- VHGIWFGJIHTASW-FXQIFTODSA-N Met-Ala-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O VHGIWFGJIHTASW-FXQIFTODSA-N 0.000 description 1
- MTBVQFFQMXHCPC-CIUDSAMLSA-N Met-Glu-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MTBVQFFQMXHCPC-CIUDSAMLSA-N 0.000 description 1
- GPAHWYRSHCKICP-GUBZILKMSA-N Met-Glu-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GPAHWYRSHCKICP-GUBZILKMSA-N 0.000 description 1
- RNAGAJXCSPDPRK-KKUMJFAQSA-N Met-Glu-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 RNAGAJXCSPDPRK-KKUMJFAQSA-N 0.000 description 1
- XKJUFUPCHARJKX-UWVGGRQHSA-N Met-Gly-His Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 XKJUFUPCHARJKX-UWVGGRQHSA-N 0.000 description 1
- AEQVPPGEJJBFEE-CYDGBPFRSA-N Met-Ile-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AEQVPPGEJJBFEE-CYDGBPFRSA-N 0.000 description 1
- JYPITOUIQVSCKM-IHRRRGAJSA-N Met-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCSC)N JYPITOUIQVSCKM-IHRRRGAJSA-N 0.000 description 1
- FXBKQTOGURNXSL-HJGDQZAQSA-N Met-Thr-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O FXBKQTOGURNXSL-HJGDQZAQSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- DPUOLKQSMYLRDR-UBHSHLNASA-N Phe-Arg-Ala Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 DPUOLKQSMYLRDR-UBHSHLNASA-N 0.000 description 1
- LGBVMDMZZFYSFW-HJWJTTGWSA-N Phe-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=CC=C1)N LGBVMDMZZFYSFW-HJWJTTGWSA-N 0.000 description 1
- KJJROSNFBRWPHS-JYJNAYRXSA-N Phe-Glu-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KJJROSNFBRWPHS-JYJNAYRXSA-N 0.000 description 1
- JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 description 1
- HNFUGJUZJRYUHN-JSGCOSHPSA-N Phe-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HNFUGJUZJRYUHN-JSGCOSHPSA-N 0.000 description 1
- DOXQMJCSSYZSNM-BZSNNMDCSA-N Phe-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O DOXQMJCSSYZSNM-BZSNNMDCSA-N 0.000 description 1
- BNRFQGLWLQESBG-YESZJQIVSA-N Phe-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O BNRFQGLWLQESBG-YESZJQIVSA-N 0.000 description 1
- OAOLATANIHTNCZ-IHRRRGAJSA-N Phe-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N OAOLATANIHTNCZ-IHRRRGAJSA-N 0.000 description 1
- QSWKNJAPHQDAAS-MELADBBJSA-N Phe-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O QSWKNJAPHQDAAS-MELADBBJSA-N 0.000 description 1
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 108020005089 Plant RNA Proteins 0.000 description 1
- KIZQGKLMXKGDIV-BQBZGAKWSA-N Pro-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 KIZQGKLMXKGDIV-BQBZGAKWSA-N 0.000 description 1
- VCYJKOLZYPYGJV-AVGNSLFASA-N Pro-Arg-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VCYJKOLZYPYGJV-AVGNSLFASA-N 0.000 description 1
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 1
- XUSDDSLCRPUKLP-QXEWZRGKSA-N Pro-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 XUSDDSLCRPUKLP-QXEWZRGKSA-N 0.000 description 1
- SKICPQLTOXGWGO-GARJFASQSA-N Pro-Gln-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)N)C(=O)N2CCC[C@@H]2C(=O)O SKICPQLTOXGWGO-GARJFASQSA-N 0.000 description 1
- WSRWHZRUOCACLJ-UWVGGRQHSA-N Pro-Gly-His Chemical compound C([C@@H](C(=O)O)NC(=O)CNC(=O)[C@H]1NCCC1)C1=CN=CN1 WSRWHZRUOCACLJ-UWVGGRQHSA-N 0.000 description 1
- BCNRNJWSRFDPTQ-HJWJTTGWSA-N Pro-Ile-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BCNRNJWSRFDPTQ-HJWJTTGWSA-N 0.000 description 1
- WHNJMTHJGCEKGA-ULQDDVLXSA-N Pro-Phe-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WHNJMTHJGCEKGA-ULQDDVLXSA-N 0.000 description 1
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 1
- FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 1
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 description 1
- MOINZPRHJGTCHZ-MMWGEVLESA-N Ser-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N MOINZPRHJGTCHZ-MMWGEVLESA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 1
- STGXWWBXWXZOER-MBLNEYKQSA-N Thr-Ala-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 STGXWWBXWXZOER-MBLNEYKQSA-N 0.000 description 1
- MQBTXMPQNCGSSZ-OSUNSFLBSA-N Thr-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)O)CCCN=C(N)N MQBTXMPQNCGSSZ-OSUNSFLBSA-N 0.000 description 1
- WLDUCKSCDRIVLJ-NUMRIWBASA-N Thr-Gln-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O WLDUCKSCDRIVLJ-NUMRIWBASA-N 0.000 description 1
- ZQUKYJOKQBRBCS-GLLZPBPUSA-N Thr-Gln-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O ZQUKYJOKQBRBCS-GLLZPBPUSA-N 0.000 description 1
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 1
- JQAWYCUUFIMTHE-WLTAIBSBSA-N Thr-Gly-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JQAWYCUUFIMTHE-WLTAIBSBSA-N 0.000 description 1
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 1
- QYDKSNXSBXZPFK-ZJDVBMNYSA-N Thr-Thr-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYDKSNXSBXZPFK-ZJDVBMNYSA-N 0.000 description 1
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 1
- FBQHKSPOIAFUEI-OWLDWWDNSA-N Thr-Trp-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O FBQHKSPOIAFUEI-OWLDWWDNSA-N 0.000 description 1
- MYNYCUXMIIWUNW-IEGACIPQSA-N Thr-Trp-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MYNYCUXMIIWUNW-IEGACIPQSA-N 0.000 description 1
- 241000545405 Tripterygium Species 0.000 description 1
- VIYFRTDWJXBEDM-UHFFFAOYSA-N Triptophenolide Natural products CC(C)c1ccc2c(CCC3C4=COC(=O)C4=CCC23C)c1O VIYFRTDWJXBEDM-UHFFFAOYSA-N 0.000 description 1
- TUUXFNQXSFNFLX-XIRDDKMYSA-N Trp-Met-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N TUUXFNQXSFNFLX-XIRDDKMYSA-N 0.000 description 1
- XOLLWQIBBLBAHQ-WDSOQIARSA-N Trp-Pro-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O XOLLWQIBBLBAHQ-WDSOQIARSA-N 0.000 description 1
- RIFVTNDKUMSSMN-ULQDDVLXSA-N Tyr-His-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O RIFVTNDKUMSSMN-ULQDDVLXSA-N 0.000 description 1
- CDBXVDXSLPLFMD-BPNCWPANSA-N Tyr-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDBXVDXSLPLFMD-BPNCWPANSA-N 0.000 description 1
- AKRHKDCELJLTMD-BVSLBCMMSA-N Tyr-Trp-Arg Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N AKRHKDCELJLTMD-BVSLBCMMSA-N 0.000 description 1
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 1
- SCBITHMBEJNRHC-LSJOCFKGSA-N Val-Asp-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N SCBITHMBEJNRHC-LSJOCFKGSA-N 0.000 description 1
- SZTTYWIUCGSURQ-AUTRQRHGSA-N Val-Glu-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SZTTYWIUCGSURQ-AUTRQRHGSA-N 0.000 description 1
- MGVYZTPLGXPVQB-CYDGBPFRSA-N Val-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](C(C)C)N MGVYZTPLGXPVQB-CYDGBPFRSA-N 0.000 description 1
- RQOMPQGUGBILAG-AVGNSLFASA-N Val-Met-Leu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O RQOMPQGUGBILAG-AVGNSLFASA-N 0.000 description 1
- IECQJCJNPJVUSB-IHRRRGAJSA-N Val-Tyr-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(O)=O IECQJCJNPJVUSB-IHRRRGAJSA-N 0.000 description 1
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
- 150000000150 abietanes Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 229930188824 alisol Natural products 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- HPAIKDPJURGQLN-UHFFFAOYSA-N glycyl-L-histidyl-L-phenylalanine Natural products C=1C=CC=CC=1CC(C(O)=O)NC(=O)C(NC(=O)CN)CC1=CN=CN1 HPAIKDPJURGQLN-UHFFFAOYSA-N 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 108010077158 leucinyl-arginyl-tryptophan Proteins 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 108010068488 methionylphenylalanine Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000001575 tandem quadrupole mass spectrometry Methods 0.000 description 1
- 108010087432 terpene synthase Proteins 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P15/00—Preparation of compounds containing at least three condensed carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
- C12N9/0081—Cholesterol monooxygenase (cytochrome P 450scc)(1.14.15.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/102—Plasmid DNA for yeast
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及一种酶，所述酶具有催化松香烷型三环二萜化合物的C‑14和C‑12位羟化，以及催化C环芳香化的作用，所述酶为一种雷公藤细胞色素p450氧化酶CYP82D263，本发明还涉及编码所述酶的多核苷酸CYP82D263，所述酶催化实验证实具有催化雷公藤甲素生物合成中间体脱氢松香酸(dehydroabieticacid)和次丹参酮二烯(miltiradiene)C‑14和C‑12位羟基化的功能、以及C环芳香化的作用，为雷公藤甲素中间体合成生物学生产提供了重要元件，对雷公藤甲素等松香烷型三环二萜化合物的合成调控具有重要的意义。
Description
技术领域
本发明涉及一种雷公藤细胞色素P450氧化酶，以及编码所述酶的多核苷酸，所述酶可用于松香烷型三环二萜类化合物的关键碳-14位(C-14)、碳-12位(C-12)位生物合成，属于药用植物基因工程领域。
背景技术
雷公藤甲素是药用植物雷公藤(Tripterygium wilfordii Hook.f.)的主要活性成分之一，是一种具有3个环氧基团及一个α,β不饱和五元内酯环结构的松香烷型二萜化合物，同时也是雷公藤中活性最高的环氧二萜内酯化合物(Zhou ZL,et al.Triptolide:structural modifications,structure-activity relationships,bioactivities,clinical development and mechanisms[J].Nat.Prod.Rep.2012,29)。雷公藤甲素具有显著的抗炎、免疫抑制、抗肿瘤等生物活性，对类风湿性关节炎、系统性红斑狼疮等自身免疫系统疾病，胰腺癌、肺癌等多种癌症具有较好的疗效，同时研究表明，雷公藤甲素对老年痴呆症、帕金森病等中枢神经系统疾病展现出潜在的药用价值，基于雷公藤甲素构效机制研发的多种衍生药物已进入临床试验阶段(Zhou ZL,et al.Triptolide:structuralmodifications,structure-activity relationships,bioactivities,clinicaldevelopment and mechanisms.Nat.Prod.Rep.,2012,29；TitovDV,et al.XPB,a subunitof TFIIH,is a target of the natural product triptolide.Nat.Chem.Biol,2011,7)。当前，雷公藤甲素的获取方式依赖传统的植物提取和化学合成，受限于植物较长的生长周期和化合物复杂的手性结构，其获取量难以满足临床科研和治疗的大量需求。近年来，利用合成生物学策略对雷公藤甲素生物合成途径进行解析，有望通过这种新颖且可持续的生产方式获取雷公藤甲素及其中间体。
当前，雷公藤甲素生物合成途径的解析，已成功表征了萜类合酶TPS7v2和TPS27v2环化形成雷公藤甲素关键母核结构——次丹参酮二烯(Su P,et al.Identification andfunctional characterization of diterpene synthases for triptolidebiosynthesis from Tripterygium wilfordii.Plant J.,2018,93)，并揭示了其生物合成下游途径第一个细胞色素P450 CYP728B70基因(Tu L,et al.Genome of Tripterygiumwilfordii and identification of cytochrome P450 involved in triptolidebiosynthesis.Nat.Commun.,2020,11)，完成了从二萜共同前体GGPP到次丹参酮二烯的母核环化，再经双键重排自发转化为阿松香三烯，最后到脱氢松香酸的羧基化过程。然而，参与从脱氢松香酸到雷公藤甲素的多个位点的羟化酶未被发掘。由此可见，揭示雷公藤甲素的羟基化机制对雷公藤甲素的生物合成及结构修饰具有重要意义。
发明内容
本发明的第一方面，提供了一种分离的酶，所述酶参与三环二萜类化合物的C-14和C-12位羟基化过程，尤其是松香烷型二萜类化合物的C-14和C-12位羟基化过程，本发明所述酶，还可催化松香烷型三环二萜类化合物的C环芳香化。
本发明中，所述分离的酶，是从药用植物雷公藤中分离得到的细胞色素p450氧化酶(以下用CYP82D263表示)，参与雷公藤松香烷型二萜类化合物C-14和C-12位羟化的合成过程，以及C环芳香化，尤其是雷公藤甲素C-14和C-12位羟化的关键酶，所述酶具有SEQ IDNO：2所示的氨基酸序列，或SEQ ID NO：2所示氨基酸序列经取代、缺失或增加一个或多个氨基酸其功能相同的肽。
可以在CYP82D263酶中进行氨基酸序列改变以便最少破坏对生物学活性必须的高级结构。例如，当CYP82D263酶包含一个或多个螺旋时，将改变氨基酸残基以便不破坏螺旋的几何学和其中的构象改变将使一些关键功能(例如分子与其结合伙伴的结合)减弱的其它分子成分。氨基酸序列改变的效果可以通过例如以上公开的计算机模拟进行预测，或通过晶体结构分析进行测定(例如Lapthorn等，Nat.Struct.Biol.2:266-268,1995)。本领域熟知的其它技术对改变蛋白和标准分子(例如天然蛋白)的折叠进行比较，例如，可以比较变体和标准分子中的半胱氨酸分布情况。质谱和使用还原烷基化的化学修饰为测定与二硫键相关的或未形成这些键的半胱氨酸残基提供了方法(Bean,et al.Anal.Biochem.1992,201:216-266；Gray,Protein Sci.1993,2:1732-1748；Patterson,et al.Anal.Chem.1994,66:3727-3732)。一般认为如果修饰的分子与标准分子具有不相同的半胱氨酸分布情况，则折叠受到影响。另一个用于测量这点的被接受的熟知方法是园二色谱(CD)。测量和比较修饰分子和标准分子产生的CD谱是常规的(Johnson,Proteins.1990,7:205-214)。晶体学是另一个分析折叠和结构的熟知方法，核磁共振(NMR)、消化肽作图和表位作图也是分析折叠及蛋白质和多肽之间的结构相似性的已知方法(Schaanan,et al.Science.1992,257:961-964)。
本发明中，CYP82D263酶的变异体形式包括：同源序列、保守性变异体、等位变异体、天然突变体、诱导突变体、在高或低的严谨条件下能与CYP82D263酶编码基因杂交的DNA所编码的蛋白。
本发明的第二方面，提供了一种编码本发明所述酶的多核苷酸(或称雷公藤细胞色素P450氧化酶编码基因，以下可用CYP82D263表示)，所述多核苷酸优选具有SEQ ID NO：1所示核苷酸序列及其简并序列。该简并序列指位于SEQ ID NO：1序列核苷酸中，有一个或多个密码子被编码相同氨基酸的简并密码子所取代后而产生的序列。由于密码子的简并性，所以与SEQ ID NO：1核苷酸序列同源性低至约70％的简并序列也能编码出SEQ ID NO：2所述酶的氨基酸序列。还包括能在中度严谨条件下，更佳的在高度严谨条件下与SEQ ID NO：1中从核苷酸162-1566位的核苷酸序列杂交的核苷酸序列。还包括与SEQ ID NO：1的核苷酸序列的同源性至少70％，较佳地至少80％，更佳地至少90％，最佳地至少95％的核苷酸序列。还包括能编码具有与天然的雷公藤细胞色素P450氧化酶相同功能的蛋白的SEQ ID NO：1中开放阅读框序列的变异形式。这些变异形式包括(但不限于)若干个(通常为1-90个，较佳地1-60个，更佳地1-20个，最佳地1-10个)核苷酸的缺失、插入和/或取代，以及在5′和/或3′端添加数个(通常为60个以内，较佳地为30个以内，更佳地为10个以内，最佳地为5个以内)核苷酸。
本发明的第三方面，提供了一种包含本发明第二方面所述多核苷酸的表达载体，所述的表达载体，如可以是选自pESC系列的表达载体。
本发明中，可选用本领域已知的各种载体，如市售的载体，包括质粒、粘粒等。在生产本发明CYP82D263酶时，可以将CYP82D263酶编码基因的核苷酸序列可操作地连接于表达调控序列，从而形成雷公藤P450表达载体。所述“可操作地连接”当指DNA区段时表示这些区段按照一定方式排列以致它们可以协调地为其预期的目的发挥作用，例如在启动子中起始转录并前行通过编码区段到达终止子。也指这样一种状况：即线性DNA序列的某些部分能够影响同一线性DNA序列其它部分活性，例如，如果信号肽DNA作为前提表达并参与多肽的分泌，那么信号肽(分泌前导序列)DNA就是可操作地连接于多肽DNA；如果启动子控制序列转录，那么它是可操作地连接于编码序列；如果核糖体结合位点被置于能使其翻译的位置时，那么它是可操作地连接于编码序列。一般，“可操作地连接”意味着相邻，而对于分泌前导序列则意味着在阅读框中相邻。
本发明第四方面，提供了一种包含本发明第二方面所述多核苷酸、或本发明第三方面所述表达载体的重组宿主菌，所述宿主菌为酵母菌，如BY系列酵母菌、WAT系列酵母菌等，如BY4741、BY4742、BY-T20、BY-PS2等。
本发明述宿主菌，包含本发明所述编码CYP82D263酶或其变体的多核苷酸分子，或在严谨条件下可与所述多核苷酸分子进行杂交的核苷酸分子，或包含本发明上述的表达载体。所述的宿主细胞选自：细菌细胞(如大肠杆菌)、真菌细胞(如酵母细胞)、昆虫细胞、哺乳动物细胞或植物细胞，优选为酵母细胞或植物细胞。
特别有意义的酵母包括酿酒酵母(Saccharomyces cerevisiae)、巴斯德毕赤酵母(Pichia pastoris)和甲醇毕赤酵母(Pichia methanolica)等。用外源DNA转化酿酒酵母细胞和从其中制备重组多肽的方法公开在例如Kawassaki，美国专利US4599311，US4931373、US4870008、US5037743、US4845075等中。通过选择标记所确定的表型，通常是药物抗性或在缺少特定养分(例如亮氨酸)时的生长能力，选择转化细胞。用于酿酒酵母的优选载体系统如可以是pESC系列表达载体。用于酵母的适宜启动子和终止子包括来自于糖酵解基因(US4599311、US4615974和US4977092)和醇脱氢酶的。用于其它酵母，包括多形汉逊氏酵母、乳克鲁维氏酵母、脆壁克鲁维氏酵母、巴斯德毕赤酵母、甲醇毕赤酵母、季也蒙氏毕赤酵母和麦芽糖假丝酵母的转化系统也是本领域已知的。
根据常规方法在含有养分和其它对于所选宿主细胞的生长必须成分的培养基中培养转化的或转染的宿主细胞。多种适宜的培养基，包括已知成分培养基和复杂培养基，是本领域已知的，一般包括碳源、氮源、必需氨基酸、维生素和矿物质。如果需要，培养基还可以含有诸如生长因子或血清这样的成分。生长培养基一般通过例如药物筛选或缺少可由表达载体携带的或共转染至宿主细胞中的选择标记补充的必需养分来选择含有外源添加DNA的细胞。通过常规方式，如振摇小三角瓶或发酵罐通气给液体培养物提供充足的空气。
本发明编码CYP82D263酶的多核苷酸全长序列或其片段通常可以用PCR扩增法、重组法或人工合成的方法获得。对于PCR扩增法，可根据本发明所公开的有关核苷酸序列设计引物，并用市售的cDNA库或按本领域技术人员已知的常规方法制备cDNA库作为模板，扩增而得有关序列。当序列较长时，往往需要进行两次或多次PCR扩增，然后再将各次扩增出的片段按正确次序拼接在一起。一旦获得了有关的序列，就可以用重组法来大批量地获得有关序列。这通常是将其克隆入载体，再转入细胞，然后通过常规方法从增殖后的宿主细胞中分离得到有关序列。此外，还可通过化学合成将突变体引入本发明蛋白序列中。除了用重组法产生之外，本发明蛋白的片段还可用固相技术，通过直接合成肽而加以生产(Stewart,etal.Solid-Phase Pedtide Synthesis,J.Am.Chem.Soc.1963,85:2149-2154)。在体外合成蛋白质可以用手工或自动进行。例如，可以用Applied Biosystems的431A型肽合成仪(Foster City，CA)来自动合成肽。可以分别化学合成本发明蛋白的各片段，然后用化学方法加以连接以产生全长的分子。
本发明将克隆得到的CYP82D263基因构建表达载体，经催化实验证实其完成松香烷型三环二萜C-14和C-12位羟基化过程，以及催化C环芳香化，即氧化次丹参酮二烯生成C环芳香化产物阿松香三烯、C-12羟化产物12-羟基阿松香三烯及C-14羟化产物14-羟基阿松香三烯，氧化脱氢松香酸生成C-12羟化产物12-羟基-脱氢松香酸及C-14羟化产物14-羟基-脱氢松香酸。
因此，本发明的第五方面，提供了CYP82D263、或其编码基因CYP82D263、或包含所述编码基因CYP82D263的表达载体、以及包含所述表达载体的宿主菌，在调节和/或合成二萜类化合物中的应用。
本发明中，其中所述催化松香烷型三环二萜类化合物C-12和C-14位羟基化(或所述C-14和C-12位羟基化)，是指在催化生产的产物中，包含C-12位羟基化的单一位点羟化产物和C-14位羟基化的单一位点羟化产物，但不包含C-12位和C-14位两个位点同时羟基化的双羟基化产物。
本发明中，所述的二萜类化合物优选为松香烷型三环二萜类化合物，如脱氢松香酸或次丹参酮二烯。
本发明中，所述松香烷型三环二萜类化合物，对C环芳香化时，一个优选的实施方案是，C环具有两个双键。
本发明的第六方面，提供了一种组合物，包含本发明第一方面所述的酶，以及细胞色素P450氧化还原酶(cytochrome P450 reductase,CPR)如TwCPR3。本发明中，将未羟化的三环二萜类化合物以底物喂养的方式加入到获得的重组酵母菌中/或加入到重组酵母菌表达后分离所得的蛋白中，生物合成获得C-12和C-14位羟化的松香烷型三环二萜类化合物。
本发明的第七方面，提供了一种制备C-14和C-12位羟化的松香烷型二萜类化合物的方法，所述方法包括：
(1)将CYP82D263的基因表达盒插入真核表达载体中，制备表达所述酶CYP82D263的重组酵母菌；
(2)以次丹参酮二烯为底物，加入到步骤(1)中获得的酶CYP82D263的重组酵母菌中，催化获得阿松香三烯、12-羟基-阿松香三烯和14-羟基-阿松香三烯；或者
(3)以脱氢松香酸为底物，加入到步骤(1)中获得的酶CYP82D263的重组酵母菌，催化获得14-羟基-脱氢松香酸和12-羟基-脱氢松香酸；
在一个优选的实施方案中，所述制备松香烷型二萜类化合物的方法，其中步骤(1)所述的真核表达载体为pESC-Leu，所述酶CYP82D263的编码基因插在NotI、SpeI位点。
本发明的第八方面，提供的CYP82D263和CYP82D263基因是植物中克隆获得的，其直接参与松香烷型二萜类化合物C-14和C-12位羟化的生物合成，典型地化合物如脱氢松香酸或次丹参酮二烯(雷公藤甲素生物合成前体)，因此可以通过基因工程技术进一步验证基因对雷公藤甲素生物合成的直接作用。基因枪介导的CYP82D263基因干扰结果显示，转入含CYP82D263基因的干扰载体的悬浮细胞对比转入空载的悬浮细胞，CYP82D263基因表达量显著下降，相对应的雷公藤甲素含量显著降低；当过表达CYP82D263时，含有C-14和C-12羟化结构的松香烷型二萜化合物，如雷公藤甲素、雷酚内酯、14-羟基-脱氢松香酸和12-羟基-阿松香三烯含量较对照组分别出现1.68倍(P<0.05)、1.57倍(P<0.05)、1.36倍(P<0.01)和1.48倍(P<0.05)提高，表明CYP82D263具有C-14和C-12位羟基化功能。CYP82D263基因可用于利用合成生物学策略来提高雷公藤甲素含量的研究和产业化中，尤其可用于中药雷公藤的品质改良和栽培育种，对于缓解雷公藤药源匮乏问题有较好的促进作用。
附图说明
图1为CYP82D263基因克隆琼脂糖凝胶电泳图(Marker为Trans2K PlusII DNAMarker，核酸分子量标准，条带由上往下分别为8000、5000、3000、2000、1000、750、500、250、100bp)，CYP82D263表示CYP82D263基因。
图2为酵母体内CYP82D263功能表征(催化从次丹参酮二烯)及生成阿松香三烯相对含量。
图3为CYP82D263功能表征(催化脱氢松香酸)。
图4为雷公藤悬浮细胞CYP82D263基因干扰及雷公藤甲素的相对含量。
图5为雷公藤悬浮细胞CYP82D263基因过表达时松香烷类二萜化合物相对含量。
具体实施方式
以下结合具体实施例，进一步阐述本发明。这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中如未注明特殊的实验方法，通常按照常规条件或依据制造厂商建议的条件方法。此外，任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅为本发明表明基因功能所作示范之用。
下述实施例中的雷公藤悬浮细胞在文献“雷公藤4-(5’-二磷酸胞苷)-2-C-甲基-D-赤藓醇激酶基因的全长克隆与表达分析.中国中药杂志,2015,40(21)”中公开过，公众可从首都医科大学分子生药与中药资源实验室获得。
实施例一、雷公藤CYP82D263基因克隆(图1)
首先，使用
Super总RNA提取试剂盒(Promega)进行操作：
(1)取约10mg雷公藤悬浮细胞样品置于2mL的离心管中，液氮环境下粉碎均匀，迅速用混合型研磨仪(MM400，Retsch)粉碎2min；
(2)向装有粉碎样品的EP管中迅速加入500μL RNA裂解液，上下颠倒离心管3-4次，使样品充分裂解；
(3)继续加入500μL RNA稀释液，用移液枪吸打混匀，4℃，14 000rpm，离心5min；
(4)取上清液于新的无菌2mL离心管中，加入0.5倍体积无水乙醇，颠倒离心管以充分混匀；
(5)将混合液分次转入离心柱中，4℃，12 000rpm，离心1min，弃滤液；
(6)向离心柱中加入600μL RNA洗液，4℃，12 000rpm，离心45s，弃滤液；
(7)向离心柱中加入50μL DNA酶I，室温环境孵育15min；
(8)向离心柱中加入600μL RNA洗液，4℃，12 000-14 000rpm离心45s，弃滤液，重复清洗操作一次；
(9)4℃，13 000rpm，空柱离心2min；
(10)向离心柱中加入50μL预热的无核酸水(RNase-free water)，室温静置2min，4℃，13 000rpm离心1min，收集RNA溶液。
(11)经1％琼脂糖凝胶电泳检测RNA完整度后，测定RNA浓度，可直接用于cDNA反转录合成或液氮速冻置于-80℃超低温冰箱保存。
接着，利用FastQuant RT Kit(withgDNase)进行反转录，每0.5-2μg总RNA可建立20μL以下反应体系。在冰上进行操作，为提高反应体系配制准确性，可根据反应需要提前配制混合液，再分装到每个PCR反应管中。
(1)去除基因组DNA步骤：按照如下体系配制混合液，充分混匀并短暂离心。42℃孵育3min，冰上冷却；
5×gDNABuffer 2.0μL
TotalRNA 50ng-2μg
RNase-FreeddH2O 补足至10μL
(2)按照如下体系配置反转录反应混合液；
(3)第一链cDNA反转录反应体系：(2)中反转录反应混合液，加入到(1)去除DNA的反应液中，充分混匀，并于42℃，孵育15min，95℃，孵育3min；
(4)反应完成后，产物置于冰上停止反应，得到的cDNA置于-20℃保存。
最后，基因全长克隆及产物纯化
根据转录组P450基因全长cDNA序列，设计全长克隆的特异性引物(F：ATGGAGTTTCTTCTGTCACTCCC，R：TCAAATACACTCCATATAGAGATGACC)，使用2×Phanta MaxMaster Mix(延伸速度1-2kb·min-1)进行PCR反应，反应体系如下：
PCR反应条件：95℃30s；95℃15s，56℃15s，72℃1.5min 35个循环；72℃7min；4℃保持。反应结束后取5μL反应产物，加1μL 6×Loading Buffer，进行1.0％琼脂糖凝胶电泳(180V，约10min)，检测目标条带位置正确后，使用1.5％琼脂糖凝胶电泳(150V，约25min)充分分离DNA并切取目标条带。
如图1可见，克隆获得条带大小为1587bp的CYP82D263片段。
使用Thermo Scientfic GeneJET胶回收试剂盒回收纯化DNA：
(1)加入等比量的Binding Buffer(每0.1g琼脂糖凝胶加100μL Buffer)至含有胶的2mL离心管中，60℃条件下孵育凝胶混合物约10min保证完全溶解；
(2)转移凝胶溶液至GeneJET纯化柱，使用离心机12 000g离心1min，弃去收集管中废液；
(3)加入700μL Wash Buffer到纯化柱，12 000g离心1min，弃去废液；
(4)空柱12 000g，离心1min，彻底去除残余的Wash Buffer；
(5)将纯化柱转移到干净无菌的已标记的1.5mL离心管，加入60℃预热的无菌水30-50μL，室温孵育2min，12 000g离心2min彻底收集DNA；
(6)纯化的DNA可直接用于下一步实验或于-20℃储存。
实施例二、高产次丹参酮二烯工程酵母体内CYP82D263功能表征
本部分使用次丹参酮二烯高产工程菌BY-PS2(为BY系酵母菌整合两个相同的SmMS-SmCPS1模块，详见Tu L,et al.Genome of Tripterygium wilfordii andidentification of cytochrome P450 involved in triptolidebiosynthesis.Nat.Commun.,2020,11)。
1.CYP82D263催化功能表征
(1)构建真核表达载体pESC-LEU::(CYP82D263+TwCPR3)
将雷公藤细胞色素P450氧化还原酶3(TwCPR3)构建至pESC-LEU上Gal 1启动子的多克隆位点MCS2(multiple cloning site)端，将CYP82D263构建至载体上Gal 10启动子的的MCS1端，载体部分采用NEB限制性内切酶SpeI-HF和SalI-HF进行双酶切反应，反应体系为：
待反应结束后，与未酶切载体和15K DNA Marker(全式金)一同进行电泳检测，确定目标大小有条带并且与未酶切样品表现形式不同，视为酶切成功，使用1.5％琼脂糖凝胶电泳(150V，约25min)和胶回收试剂盒纯化回收线性载体条带。
DNA片段准备：分别以含有雷公藤TwCPR3基因全长和CYP82D263基因全长cDNA的质粒和为模板，用特异引物(见表1)进行基因编码区的扩增，引物见表1。采用
High-Fidelity PCR超保真酶混合液进行扩增。PCR程序参数为98℃3min，1个循环；98℃10s，60℃20s，72℃60s，35个循环；72℃7min，1个循环；4℃终止反应。经电泳检测相应位置有条带，扩增产物经琼脂糖凝胶电泳分离后进行DNA片段的纯化回收。
表1真核表达载体构建引物列表
将目的片段TwCPR3、CYP82D263和线性载体连接成环状，采用无缝拼接法(同源重组原理)，利用
Ultra One Step Cloning Kit(诺唯赞)构建真核表达载体pESC-LEU::(CYP82D263+TwCPR3)。核酸定量仪检测上述目的基因片段和载体片段浓度，按照目的片段与载体片段摩尔比1:1:1配制反应体系，加入等体积2×ClonExpress Mix溶液充分混匀后，50℃反应45min。将连接产物与50μLTrans1-T1克隆感受态细胞混合，冰上静置30min，42℃水浴热激45s，冰上静置2-3min，加入500μL不含抗生素的LB液体培养基，置于37℃摇床中，180-200rpm培养1-2h，取100μL菌液涂布在含有100mg·L-1氨苄霉素的LB固体培养基上，倒置培养12-16h。经菌落筛选后，以37℃250rpm避光振荡培养约3-4h的菌液作为模板，以Gal 1、Gal 10正反引物(表1)进行阳性克隆验证，将含目的条带的菌液进行测序，获得pESC-LEU::(CYP82D263+TwCPR3)真核表达载体。
接着，真核表达载体转化酵母BY-PS2及发酵产物：将上述pESC-LEU::(CYP82D263+TwCPR3)真核表达载体和相应的空载体pESC-LEU::TwCPR3转化BY-PS2酿酒酵母，感受态细胞制作及转化具体方法如下：
(2)酵母感受态制备及转化
从SD-Ura-His+2％Glc固体平板挑取活化的BY-PS2，30℃，200rpm振荡培养至OD600达到0.8-1.0左右。室温环境，500g离心4min，去上清；加入5mL Frozen-EZ溶液1重悬菌体，室温500g离心4min，弃上清；加入0.5mL Frozen-EZ溶液2重悬菌体，每管30-50μL分装至无菌干净的1.5mL EP管中。向感受态细胞中加入0.2-1μg重组质粒pESC-LEU::(CYP82D263+TwCPR3)轻弹混合；加入500μL Frozen-EZ溶液3，混匀后于30℃孵育1-2h，取100μL孵育菌液，涂布SD-Leu-Ura-His+2％Glc平板，30℃倒置培养48-72h。
(3)阳性验证及菌液发酵
随机挑取SD-Leu-Ura-His+2％Glc平板单菌落，置于10mL SD-Leu-Ura-His+2％Glc液体培养基中，30℃，200rpm震荡培养36-48h；
阳性验证：取1μL菌液进行阳性克隆PCR反应，检测质粒成功转化BY-PS2酿酒酵母。使用2×Rapid Taq Master Mix，PCR反应体系如下，2×Rapid Taq Master Mix 10.0μL，Gal 10及Gal 1正反引物各0.8μL，菌液1.0μL，无菌水补足至20.0μL，反应程序为95℃，3min；95℃15s，56℃15s，72℃0.5min，35个循环；72℃，5min；4℃停止反应。反应结束后取8μL反应产物与2K DNA Marker进行琼脂糖凝胶电泳，检测是否含有目标条带。
将验证成功的菌液，以OD约0.1接菌至20mL SD-Leu-Ura-His+2％Glc液体培养基中，30℃，200rpm震荡培养至OD 1.0左右，离心收集菌体，以20mL SD-Leu-Ura-His+2％Gal重悬菌体，30℃，200rpm诱导发酵48-72h。
(4)发酵产物提取
以等体积乙酸乙酯提取发酵产物两次，旋干萃取液后，以0.8mL色谱级乙酸乙酯复溶2次，氮吹干，100μL色谱级乙酸乙酯复溶，12 000g高速离心10min后取上清GC-MS进样，检测使用色谱柱DB-5MS(15m，0.25mm，0.1μm)，50℃起始保持1min；40℃·min-1上升至200℃；20℃·min-1上升至240℃；1.5℃·min-1上升至246℃；40℃·min-1上升至300℃，保持3min。
结果见图2a，CYP82D263催化底物次丹参酮二烯生成三个产物，即将次丹参酮二烯的C环芳香化生成产物1：阿松香三烯，并在其C-12位羟化生成产物2：12-羟基-阿松香三烯(亦称铁锈醇)，在其C-14位羟化生成产物3：14-羟基-阿松香三烯。
2.定量产物发酵与检测
(1)载体构建
构建组成型启动CYP82D263和TwCPR3的质粒pESC-LEU::(PPGK1-CYP82D263-TADH1-PTEF2-TwCPR3-TCYC1)，引物见表2。
载体准备：载体部分采用NEB限制性内切酶SpeⅠ-HF和SalI-HF对pESC-LEU载体进行双酶切反应，反应体系为：
待反应结束后，与未酶切载体和15K的DNA Marker一同电泳检测，确定目标大小有条带并且与未酶切样品表现形式不同，视为酶切成功，大胶分离并使用胶回收试剂盒纯化回收线性载体条带。
DNA片段准备：使用
High-Fidelity PCR超保真酶分别对CYP82D263、TwCPR3和启动子PPGK1-PTEF2(PT)的质粒进行扩增，反应体系：2×Phusion HF 25.0μL，2.5μL引物F(10μM)，2.5μL引物R(10μM)，1μL质粒模板，无菌水补足至50μL。PCR程序参数为98℃3min，1个循环；98℃10s，60℃20s，72℃延伸速度1-2kb·min-1，根据条带大小设置，35个循环；72℃7min，1个循环；4℃停反应。
无缝拼接法采用
Ultra One Step Cloning Kit(诺唯赞)构建表达载体pESC-LEU::(PPGK1-CYP82D263-TADH1-PTEF2-TwCPR3-TCYC1)：检测目的基因片段和载体片段浓度，按照三个目的基因与载体片段摩尔比1:1:1:1插入片段，加入等体积2×ClonExpress Mix混合均匀后，50℃反应1h。将连接产物与50μL Trans1-T1克隆感受态细胞混合，冰上静置30min，42℃水浴热激45s，冰上静置2-3min，加入500μL不含抗生素的LB液体培养基，置于37℃摇床中，200rpm培养1-2h，取100μL菌液涂布在含有100mg·L-1氨苄霉素(Amp)的LB固体培养基上，倒置培养12-16h。经菌落筛选后，分别使用PT(MCS2)和PT(MCS1)的正反引物进行阳性克隆验证后测序，获得pESC-LEU::(PPGK1-CYP82D263-TADH1-PTEF2-TwCPR3-TCYC1)真核表达载体。
表2真核表达载体及突变载体构建引物列表
(2)表达载体转化BY-PS2及产物提取检测
将构建的真核表达载体转化次丹参酮二烯高产酵母菌BY-PS2，平板随机挑取5个独立、完整、圆润的菌落，5mL SD-Leu-Ura-His+2％Glc培养基30℃200rpm培养48-72h至菌体浑浊，Nanodrop检测菌液OD，计算各菌液加入量，以相同OD 0.1起始定量转接入新鲜的20mL SD-Leu-Ura-His+2％Glc培养基，30℃200rpm黑暗震荡，10h后加入2mL(十分之一培养基体积)正十二烷进行双向发酵，共发酵72h。待发酵结束，收集发酵液，8 000g离心5min，吸取上层正十二烷层约200μL，12 000g高速离心10min后取上清100μL GC-MS进样。检测使用色谱柱DB-5MS(15m，0.25mm，0.1μm)，50℃起始保持1min；40℃·min-1上升至200℃；20℃·min-1上升至240℃；1.5℃·min-1上升至246℃；40℃·min-1上升至300℃，保持3min。
结果见图2b。CYP82D263催化芳香化生成阿松香三烯，其催化产物含量较自发反应产量提高25.00倍。表明次丹参酮二烯芳香化虽可像文献报道的自发反应，但CYP82D263可催化实现该芳香化过程，大幅度提高阿松香三烯产量。
实施例三、CYP82D263酵母体内功能表征
1.构建真核表达载体pESC-LEU::(CYP82D263+TwCPR3)
构建真核表达载体操作同实施例二。
2.真核表达载体转化BY4741及发酵
将上述pESC-LEU::(CYP82D263+TwCPR3)真核表达载体和相应的空载体pESC-LEU::TwCPR3转化BY4741酿酒酵母，感受态细胞制作及转化具体方法如下：
(1)酵母感受态制备
采用Zymo Research Frozen-EZ酵母转化试剂盒II制作酵母感受态细胞，在超净台中无菌操作：
1)将BY4741酵母菌用接菌环划线YPD+2％葡萄糖(Glucose，Glc)固体平板，30℃倒置培养36-48h；
2)从平板上挑取新活化的单菌落，接种于10mL YPD+2％Glc液体培养基中，30℃，200rpm振荡培养至OD600达到0.8-1.0左右；
3)5810R型低温冷冻离心机于室温，500g离心4min，去上清；
4)加入5mL Frozen-EZ溶液1重悬菌体，室温500g离心4min，弃上清；
5)加入0.5mL Frozen-EZ溶液2重悬菌体，每管30-50μL分装至无菌干净的1.5mLEP管中，可直接用于后续质粒转化或逐级降温后于-80℃保存。
(2)转化酵母感受态
1)取0.2-1μg重组质粒pESC-LEU::(CYP82D263+TwCPR3)加入50μL感受态细胞，轻弹混合；
2)加入500μL Frozen-EZ溶液3，移液器吹打混匀；
3)30℃静置孵育1-2h，每30min颠倒混匀1次；
4)取100μL孵育菌液，涂布合成型营养缺陷型培养基(Synthetic DropoutMedium，SD)SD-Leu平板，30℃倒置培养48-72h。
(3)阳性验证及菌液发酵
随机挑取单菌落，置于10mL SD-Leu+2％Glc液体培养基中，30℃，200rpm震荡培养36-48h；
阳性验证：取1μL菌液进行阳性克隆PCR反应，检测质粒成功转化BY4741酿酒酵母。使用2×Rapid Taq Master Mix 10.0μL，Gal 10及Gal 1正反引物各0.8μL，菌液1.0μL，无菌水补足至20.0μL，反应程序为95℃，3min；95℃15s，56℃15s，72℃0.5min，35个循环；72℃，5min；4℃停止反应。反应结束后取8μL反应产物与2K DNA Marker(全式金)进行1.0％琼脂糖凝胶电泳(200V，约10min)，检测是否含有目标条带。
将验证成功的菌液，以OD约0.1接种至20mL SD-Leu+2％Glc液体培养基中，30℃，200rpm震荡培养至OD 1.0左右，离心收集菌体，以20mL SD-Leu+2％半乳糖(galactose，Gal)培养基(含50μM脱氢松香酸)重悬菌体，30℃，200rpm诱导发酵48-72h。
(4)发酵产物提取
1)收集发酵菌液，加入等体积乙酸乙酯20mL，低温超声1h，离心收集上层乙酸乙酯层，下层发酵液加入等体积乙酸乙酯继续超声提取1次；
2)混合萃取液，-20℃低温冷冻除去萃取液中的水分；
3)将萃取液使用旋转蒸发仪旋干有机溶剂，用0.8mL色谱级乙酸乙酯清洗旋蒸瓶内壁，复溶2次，合并复溶液；
4)高纯氮气吹干，用100μL甲醇复溶，加入100μL重氮甲烷(trimethylsilyldiazomethane,Tokyo Chemical Industry,Japan)，室温避光反应10min；
5)氮吹至干，100μL色谱级乙酸乙酯复溶，12 000g高速离心10min后取上清GC-MS进样。
(5)GC-MS检测条件
使用安捷伦7000C GC-TQ-MS，进样量1μL，进样口温度300℃，离子源温度250℃，电子能量70ev，对样品进行10-400m/z范围扫描。
色谱柱DB-5MS(30m，0.25mm，0.1μm)检测条件：50℃起始保持1min；50℃·min-1上升至240℃；1.5℃·min-1上升至255℃；50℃·min-1上升至300℃，保持5min。
结果见图3。与空白对照相比，CYP82D263催化底物脱氢松香酸，生成两个新产物(产物4和产物5)，其中产物4为主产物。经过与标准品保留时间和质谱碎片比对，产物4与14-羟基-脱氢松香酸一致，产物5与12-羟基-脱氢松香酸一致。由此结合实例二说明，CYP82D263具有对松香烷型二萜化合物C-12、C-14位羟基化功能。
实施例四、基因与代谢物和松香烷型二萜化合物生物合成
1.雷公藤悬浮细胞准备
配制MS固体培养基：Murashige&Skoog with Vitamins(Caisson Labs公司)4.43g·L-1，蔗糖(AOBOX公司)30g·L-1，2,4-D 1.0mg·L-1，IBA 1.0mg·L-1，KT 0.1mg·L-1，加水后调pH到5.8-6.0，加琼脂(Oxoid公司)8％，121℃，20min高压灭菌后温度降到60℃以下时倒入35mm细胞培养皿(每个培养皿3mL培养基)中凝固。将要继代的0.2g悬浮细胞转入细胞培养皿中心位置，倾压使细胞接触培养基，25℃，暗培养7d用于基因枪转化。
2.Gateway技术构建CYP82D263表达载体
(1)BP入门载体构建
构建干扰表达载体引物为正向：CACCGCCTTGTTCGGTTTCAGCC；反向R：CATGAAGTCTTCATCTGCAATCCCA。构建过表达片段引物为正向F：CTCCACCTGCATCGCACCATGGAGTTTCTTCTGTCACTC，反向R：GACCACCTGCATCGCCTTTCAAATACACTCCATATAGAG。
以含有雷公藤CYP82D263基因全长cDNA的载体质粒为模板，进行PCR扩增基因相应片段。DNA聚合酶采用高保真Phusion High-Fidelity CR Master Mix。PCR参数为98℃30s，1循环；98℃10s，60℃10s，72℃45s，35循环；72℃5min；4℃维持。扩增产物经Gene JET GelExtraction Kit胶回收。与TOPO载体(Invitrogen)22℃反应2h后转入大肠杆菌感受态细胞Trans1-T1，于LB+Kan培养基37℃培养，阳性克隆送测序成功后，快速质粒小提试剂盒提取质粒。
(2)干扰表达载体/过表达载体构建
入门载体和干扰表达载体各300ng，加入1μL LR酶(Invitrogen)，25℃反应3-4h，反应产物转化入Trans1-T1于LB+壮观霉素(Spe)培养基37℃培养，阳性克隆送测序成功后，用Plasmid Maxi Kit(Omega公司)质粒大提试剂盒提取质粒。
入门载体和过扰表达载体各300ng，加入1μL LR酶(Invitrogen)，25℃反应3-4h，反应产物转化入Trans1-T1于LB+Spe培养基37℃培养，阳性克隆送测序成功后，用PlasmidMaxi Kit(Omega公司)质粒大提试剂盒提取质粒。
3.基因枪介导转化
实验器材要求无菌：根据器材性质分别或结合采用高温高压灭菌、紫外照射除菌和70％乙醇杀菌。
每个质粒做5个生物学重复，即打5盘细胞，每盘2枪，共10枪。将转化空载体的悬浮细胞用作对照。将20μg质粒，5mg金粉，100μL的2.5M CaCl2，40μL的0.1M亚精胺混合，震荡2-3min，静止1min后离心约2s，弃上清；加入140μL 70％乙醇，轻弹后离心弃上清；加入140μL100％乙醇，轻弹后离心弃上清；加入100μL100％乙醇，轻弹后低速震荡2-3s，置于冰中。
将消毒后的载体膜置于铁托中，每个铁托加入10μL上述配制的载体金粉预混液，按基因枪操作规范，将铁托、阻挡网、可裂膜及雷公藤悬浮细胞分别放置在基因枪设备的相应位置上，进行基因枪转化载体，每盘细胞轰击两枪。
4.代谢物含量检测
悬浮细胞样品取至2.0mL离心管，球磨机于液氮环境下充分粉碎样品，于-80℃冷冻超过4h后，放置在冷冻干燥机(德国Christ Delta 1-20LSC)中冷冻干燥36-48h。精密称重干燥后的样品粉末20mg，以1.0mL 80％甲醇4℃提取过夜，低温40kHz，90％功率超声提取30min。离心后的上清过0.22μm PTFE滤膜，取续滤液即为供试品溶液用于后续检测。
检测使用Q Exactive HF LC-MS/MS(Thermo Scientific)，ACQUITY UPLC HSS T3色谱柱(2.1mm×100mm×1.8μm,Waters)。流动相A为0.1％甲酸-水溶液(v/v),流动相B为纯乙腈溶液。起始，30％流动相B；4min，34％流动相B；8min，52％流动相B；12min，52％流动相B；23min，77％流动相B；26min，90％流动相B进行梯度洗脱。设置流速0.4mL·min-1,进样量2.0μL,柱温40℃，正负离子扫描。
结果见图4和图5所示。图4表明，转入含CYP82D263基因干扰载体的雷公藤悬浮细胞对比转入空载的悬浮细胞，CYP82D263基因表达量显著下降，相对应的雷公藤甲素含量显著降低至对照的0.59倍。图5结果表明，当过表达CYP82D263时，含有C-14或C-12羟化结构的松香烷型三环二萜化合物，如雷公藤甲素、雷酚内酯、14-羟基-脱氢松香酸和12-羟基-阿松香三烯相对含量较对照组分别出现1.36倍(P<0.05)、1.60倍(P<0.05)、1.39倍(P<0.01)和1.48倍(P<0.05)提高。以上结果表明CYP82D263具有C-14、C-12位羟基化功能。
序列表
<110> 首都医科大学附属北京世纪坛医院
<120> 三环二萜类化合物的C-14和C-12位羟化酶
<130> TQZX2022-ZL026
<141> 2022-01-19
<160> 26
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1587
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
atggagtttc ttctgtcact cccaacaaac accatagccc ccaaaatcgt tgcagttata 60
ttactcttca taggtttaag gatattcaca aatgtcctaa aaccaaagaa atccaagaca 120
tccccaccac tagctggcgg cgcgtggcct ttgttgggcc acctccacct cctccgtggt 180
ccacagccac cacatataat attaggcaag atggccgaca aatatggtcc aatcttcaaa 240
atcaagctag gcgtgcatcc aactcttatt ataagtaact ccgagattgc caaagagtgt 300
ttgaccacac aggacaaagt cttggctggt cgtccagcga ctgtggccat ggaaatcatg 360
ggctacaaaa gggccttgtt cggtttcagc ccatacggcc catattggcg tctaacccgg 420
aaactaacaa cttctgagct tctctcgacc caacggctcg aggcacttaa acacataaga 480
gaatccgagg tgatgattgc catgaaagac ttgtaccaat catgggccga cagaaaaaca 540
gagtctgata aggttctggt ggacatgatt agagtgttcg gagacatatc ctcaaacgtg 600
atgtttagga ttgtggttgg aaaagtgtat tcgcgtaagg gtcagaggga tctgaaatgg 660
aagcaagtct tgatcgattt ttttaagttg atgggtcact ttggtgtggg tgatgcgttg 720
ccgtttttga ggtggttgga tttgggaggt gttgagaagt ccatgaaaaa gataagcaaa 780
gaattggaca attatgttga agaatggatg gaagagcaca agaggaagag actgagtcgt 840
ggtgatggga ttgcagatga agacttcatg gacgtgatgc tttcagttct tgatgatcaa 900
atggaggaga gcactggcta tactgctcat ataacgaaca aggccacgtg cttgtctatt 960
atattggcag gatccgacac aacaaggact actctaactt gggctctatc actgttactc 1020
aacaaccctg acgtcctaaa aagaactcaa caagagttag aactccatgt cggcaaagaa 1080
agactagtga atatatcaga catgaaatcc ttggtctact tccaagcagt tatgaaggaa 1140
acattgcgat tataccctgc cggaccactc tcaataccac acgaatccat ggaggattgc 1200
gtcgtagccg gttaccatgt cccagcaggg actcgaattc tcttcaatct ctggaagatt 1260
caacaggatc caaacacttg gaagaatcct tcggagttca agccagaaag gtttctgaca 1320
acacacaagg acgttgatgt taggggacgt caatttgagt tattaccatt tgggagtggt 1380
agaagaatgt gtcctggaat gcctcttgct cttcaagtca tggaacttgc gcttgctaat 1440
atgcttcatg ggttcgattt ttcaactccg aatggtgaac caatcgatat gactgaggat 1500
aatggtttgg tcacatttcg tgcaacgcca cttgaagctc tcattagtcc acgcctcccc 1560
ggtcatctct atatggagtg tatttga 1587
<210> 2
<211> 528
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Met Glu Phe Leu Leu Ser Leu Pro Thr Asn Thr Ile Ala Pro Lys Ile
1 5 10 15
Val Ala Val Ile Leu Leu Phe Ile Gly Leu Arg Ile Phe Thr Asn Val
20 25 30
Leu Lys Pro Lys Lys Ser Lys Thr Ser Pro Pro Leu Ala Gly Gly Ala
35 40 45
Trp Pro Leu Leu Gly His Leu His Leu Leu Arg Gly Pro Gln Pro Pro
50 55 60
His Ile Ile Leu Gly Lys Met Ala Asp Lys Tyr Gly Pro Ile Phe Lys
65 70 75 80
Ile Lys Leu Gly Val His Pro Thr Leu Ile Ile Ser Asn Ser Glu Ile
85 90 95
Ala Lys Glu Cys Leu Thr Thr Gln Asp Lys Val Leu Ala Gly Arg Pro
100 105 110
Ala Thr Val Ala Met Glu Ile Met Gly Tyr Lys Arg Ala Leu Phe Gly
115 120 125
Phe Ser Pro Tyr Gly Pro Tyr Trp Arg Leu Thr Arg Lys Leu Thr Thr
130 135 140
Ser Glu Leu Leu Ser Thr Gln Arg Leu Glu Ala Leu Lys His Ile Arg
145 150 155 160
Glu Ser Glu Val Met Ile Ala Met Lys Asp Leu Tyr Gln Ser Trp Ala
165 170 175
Asp Arg Lys Thr Glu Ser Asp Lys Val Leu Val Asp Met Ile Arg Val
180 185 190
Phe Gly Asp Ile Ser Ser Asn Val Met Phe Arg Ile Val Val Gly Lys
195 200 205
Val Tyr Ser Arg Lys Gly Gln Arg Asp Leu Lys Trp Lys Gln Val Leu
210 215 220
Ile Asp Phe Phe Lys Leu Met Gly His Phe Gly Val Gly Asp Ala Leu
225 230 235 240
Pro Phe Leu Arg Trp Leu Asp Leu Gly Gly Val Glu Lys Ser Met Lys
245 250 255
Lys Ile Ser Lys Glu Leu Asp Asn Tyr Val Glu Glu Trp Met Glu Glu
260 265 270
His Lys Arg Lys Arg Leu Ser Arg Gly Asp Gly Ile Ala Asp Glu Asp
275 280 285
Phe Met Asp Val Met Leu Ser Val Leu Asp Asp Gln Met Glu Glu Ser
290 295 300
Thr Gly Tyr Thr Ala His Ile Thr Asn Lys Ala Thr Cys Leu Ser Ile
305 310 315 320
Ile Leu Ala Gly Ser Asp Thr Thr Arg Thr Thr Leu Thr Trp Ala Leu
325 330 335
Ser Leu Leu Leu Asn Asn Pro Asp Val Leu Lys Arg Thr Gln Gln Glu
340 345 350
Leu Glu Leu His Val Gly Lys Glu Arg Leu Val Asn Ile Ser Asp Met
355 360 365
Lys Ser Leu Val Tyr Phe Gln Ala Val Met Lys Glu Thr Leu Arg Leu
370 375 380
Tyr Pro Ala Gly Pro Leu Ser Ile Pro His Glu Ser Met Glu Asp Cys
385 390 395 400
Val Val Ala Gly Tyr His Val Pro Ala Gly Thr Arg Ile Leu Phe Asn
405 410 415
Leu Trp Lys Ile Gln Gln Asp Pro Asn Thr Trp Lys Asn Pro Ser Glu
420 425 430
Phe Lys Pro Glu Arg Phe Leu Thr Thr His Lys Asp Val Asp Val Arg
435 440 445
Gly Arg Gln Phe Glu Leu Leu Pro Phe Gly Ser Gly Arg Arg Met Cys
450 455 460
Pro Gly Met Pro Leu Ala Leu Gln Val Met Glu Leu Ala Leu Ala Asn
465 470 475 480
Met Leu His Gly Phe Asp Phe Ser Thr Pro Asn Gly Glu Pro Ile Asp
485 490 495
Met Thr Glu Asp Asn Gly Leu Val Thr Phe Arg Ala Thr Pro Leu Glu
500 505 510
Ala Leu Ile Ser Pro Arg Leu Pro Gly His Leu Tyr Met Glu Cys Ile
515 520 525
<210> 3
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
atggagtttc ttctgtcact ccc 23
<210> 4
<211> 27
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
tcaaatacac tccatataga gatgacc 27
<210> 5
<211> 38
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
caaggagaaa aaaccccgat gagttcgagc tcggattt 38
<210> 6
<211> 45
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
aaatcaactt ctgttccatg tctcaccaaa catctcgaag atatc 45
<210> 7
<211> 47
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
gaattcaacc ctcactaaag ggcgatggag tttcttctgt cactccc 47
<210> 8
<211> 49
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
catccttgta atccatcgat actcaaatac actccatata gagatgacc 49
<210> 9
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
attttcggtt tgtattactt c 21
<210> 10
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
gttcttaata ctaacataac t 21
<210> 11
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
ggtggtaatg ccatgtaata tg 22
<210> 12
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 12
ggcaaggtag acaagccgac aac 23
<210> 13
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 13
cgcggtacta gtgtttagtt aatta 25
<210> 14
<211> 29
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 14
ctgttttata tttgttgtaa aaagtagat 29
<210> 15
<211> 46
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 15
aactaaacac tagtaccgcg atggagtttc ttctgtcact cccaac 46
<210> 16
<211> 45
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 16
tccttgtaat ccatcgatac tcaaatacac tccatataga gatga 45
<210> 17
<211> 45
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 17
ttacaacaaa tataaaacag atgagttcga gctcggattt ggttc 45
<210> 18
<211> 46
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 18
atcaacttct gttccatgtc tcaccaaaca tctcgaagat atcttc 46
<210> 19
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 19
ggtcaatgca agaaatacat at 22
<210> 20
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 20
gttcttaata ctaacataac t 21
<210> 21
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 21
tctctctatc tattctactt gt 22
<210> 22
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 22
ggcaaggtag acaagccgac aac 23
<210> 23
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 23
caccgccttg ttcggtttca gcc 23
<210> 24
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 24
catgaagtct tcatctgcaa tccca 25
<210> 25
<211> 39
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 25
ctccacctgc atcgcaccat ggagtttctt ctgtcactc 39
<210> 26
<211> 39
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 26
gaccacctgc atcgcctttc aaatacactc catatagag 39
Claims (9)
1.具有SEQ ID NO：2所示的氨基酸序列酶在催化松香烷型三环二萜类化合物C-12和C-14位羟基化，以及催化C环芳香化方面的应用。
2.根据权利要求1所述的应用，其中所述催化松香烷型三环二萜类化合物C-12和C-14位羟基化，所生成的产物为包含C-12位羟基化的单一位点羟化产物和C-14位羟基化的单一位点羟化产物，但不包含C-12位和C-14位同时羟基化的双羟化产物。
3.根据权利要求2所述的应用，其中编码所述酶的多核苷酸序列如SEQ ID NO：1所示。
4.包含权利要求3所述多核苷酸的表达载体，其含有启动子和转录终止子，其中所述启动子与所述多核苷酸可操作地连接，并且所示多核苷酸与所述转录终止子可操作地连接，所述多核苷酸可用于催化三环二萜类化合物C-12和C-14位羟基化、以及催化C环芳香化。
5.包含权利要求3所述多核苷酸、或权利要求4所述表达载体的重组宿主菌，所述宿主菌为酵母菌，如BY系酵母菌、WAT系酵母菌，所述重组酵母菌具有催化三环二萜类化合物C-12和C-14位羟基化、以及催化C环芳香化。
6.权利要求1-3中任意一权利要求所述的应用，其中所述三环二萜类化合物为松香烷型三环二萜类化合物，如次丹参酮二烯或脱氢松香酸。
7.一种催化松香烷型三环二萜类化合物C-14和C-12位羟基化，以及C环芳香化的方法，其包括：
(1)将编码权利要求1所述酶的基因表达盒插入真核表达载体中，制备表达所述酶的重组酵母菌；
(2)以C-14和C-12位未羟化的松香烷型三环二萜类化合物(如脱氢松香酸或次丹参酮二烯)为底物，加入到步骤(1)中所获得重组酵母菌中，制备获得C-14和C-12位羟化的松香烷型三环二萜类化合物；或者
以C环未形成芳香化结构的松香烷型三环二萜类化合物(如次丹参酮二烯)为底物，加入到步骤(1)中获得的表达所述酶的重组酵母菌，制备获得C环芳香化的三环二萜类化合物。
8.如权利要求7所述的方法，步骤(1)所述的真核表达载体为pESC-Leu，所述酶的编码基因插入到NotI、SpeI位点；所述三环二萜类化合物为松香烷型三环二萜类化合物。
9.权利要求1所述酶、或权利要求3所述多核苷酸分子在雷公藤植物栽培育种中的应用，所述的应用作为催化植物中松香烷型三环二萜类化合物C-12和C-14位羟基化，以及C环芳香化，以促进雷公藤有效成分的生物合成。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210059174.XA CN114410726B (zh) | 2022-01-19 | 2022-01-19 | 三环二萜类化合物的c-14和c-12位羟化酶 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210059174.XA CN114410726B (zh) | 2022-01-19 | 2022-01-19 | 三环二萜类化合物的c-14和c-12位羟化酶 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114410726A true CN114410726A (zh) | 2022-04-29 |
| CN114410726B CN114410726B (zh) | 2024-03-26 |
Family
ID=81273967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210059174.XA Active CN114410726B (zh) | 2022-01-19 | 2022-01-19 | 三环二萜类化合物的c-14和c-12位羟化酶 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114410726B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107058418A (zh) * | 2016-12-12 | 2017-08-18 | 首都医科大学 | 雷公藤二萜合酶TwCPS1在制备松香烷型二萜化合物中的应用 |
| CN108866029A (zh) * | 2018-08-08 | 2018-11-23 | 首都医科大学 | 雷公藤三萜合酶TwOSC3及其编码基因与应用 |
| CN110747178A (zh) * | 2019-11-08 | 2020-02-04 | 首都医科大学 | 雷公藤细胞色素p450氧化酶在制备松香烷型二萜化合物中的应用 |
| WO2020029564A1 (zh) * | 2018-08-08 | 2020-02-13 | 首都医科大学 | 雷公藤三萜合酶TwOSC1及其编码基因与应用 |
| CN113265381A (zh) * | 2021-04-20 | 2021-08-17 | 首都医科大学 | 一种分离的cyp450蛋白及其编码基因与应用 |
-
2022
- 2022-01-19 CN CN202210059174.XA patent/CN114410726B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107058418A (zh) * | 2016-12-12 | 2017-08-18 | 首都医科大学 | 雷公藤二萜合酶TwCPS1在制备松香烷型二萜化合物中的应用 |
| CN108866029A (zh) * | 2018-08-08 | 2018-11-23 | 首都医科大学 | 雷公藤三萜合酶TwOSC3及其编码基因与应用 |
| WO2020029564A1 (zh) * | 2018-08-08 | 2020-02-13 | 首都医科大学 | 雷公藤三萜合酶TwOSC1及其编码基因与应用 |
| CN110747178A (zh) * | 2019-11-08 | 2020-02-04 | 首都医科大学 | 雷公藤细胞色素p450氧化酶在制备松香烷型二萜化合物中的应用 |
| CN113265381A (zh) * | 2021-04-20 | 2021-08-17 | 首都医科大学 | 一种分离的cyp450蛋白及其编码基因与应用 |
Non-Patent Citations (1)
| Title |
|---|
| "PREDICTED: Tripterygium wilfordii cytochrome P450 CYP82D47-like (LOC120010094), mRNA", NCBI REFERENCE SEQUENCE: XM_038860792.1, pages 3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114410726B (zh) | 2024-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110747178B (zh) | 雷公藤细胞色素p450氧化酶在制备松香烷型二萜化合物中的应用 | |
| WO2020029564A1 (zh) | 雷公藤三萜合酶TwOSC1及其编码基因与应用 | |
| CN108866029B (zh) | 雷公藤三萜合酶TwOSC3及其编码基因与应用 | |
| CN116987603A (zh) | 一种高产大麻萜酚酸的重组酿酒酵母菌株及其构建方法与应用 | |
| CN105441462B (zh) | 一种三七转录因子基因PnERF1及其应用 | |
| CN114525214B (zh) | 一种工程益生菌的构建方法及其应用 | |
| CN113265381B (zh) | 一种分离的cyp450蛋白及其编码基因与应用 | |
| CN109136119B (zh) | 微生物及其用途 | |
| CN114410726B (zh) | 三环二萜类化合物的c-14和c-12位羟化酶 | |
| CN109136120B (zh) | 微生物及其用途 | |
| CN113528365B (zh) | 产大麻二酚的重组酿酒酵母、其构建方法以及应用 | |
| CN114480312B (zh) | 一种松香烷型三环二萜类化合物c-14位羟化酶 | |
| CN115873836A (zh) | 一种橙花叔醇合成酶及应用 | |
| CN112410353B (zh) | 一种fkbS基因、含其的基因工程菌及其制备方法和用途 | |
| CN112646834A (zh) | 一种羽扇豆醇衍生物及其合成方法和应用 | |
| CN109609522B (zh) | 博落回二氢苯并菲啶氧化酶基因优化序列及其应用 | |
| CN107903227B (zh) | 琥珀酸酐类化合物、与其相关的基因和蛋白及其制备方法 | |
| CN113444737A (zh) | 细胞色素p450酶及其在合成灵芝三萜类化合物中的应用 | |
| CN108504640A (zh) | 甾体化合物侧链修饰基因及其应用 | |
| CN114774443B (zh) | 生产小白菊内酯的重组酿酒酵母菌株及其构建方法 | |
| CN115247183B (zh) | 重组微生物的构建方法、相关生物材料及其应用 | |
| CN116445430A (zh) | 一种细胞色素p450氧化酶及其编码基因和应用 | |
| CN114196641B (zh) | 一种甾体C14α羟化酶、表达载体和工程菌及其应用 | |
| CN112322592B (zh) | 一种参与紫草素生物合成的cyp76b100蛋白及其编码基因与应用 | |
| CN113308447B (zh) | 拟南芥ugt74f2在催化苯乳酸合成苯乳酰葡萄糖中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |